Triptax

Triptax is a drug which is under development for the treatment of depressive disorders and treatment-resistant depression.^[1][2][3][4] Its mechanism of action has not been defined.^[1][2] The drug is being developed by Biomind Labs.^[1][2] As of December 2022, it is in the preclinical research stage of development.^[1][2] The chemical structure of Triptax does not yet seem to have been disclosed, but it is described as a new chemical entity.^[1][4] Aside from Triptax, Biomind Labs is also developing a variety of defined serotonergic agents and serotonergic psychedelics for treatment of various conditions.^[5]

Triptax

Clinical data
Other names	Triptax™
Drug class	Undefined[1][2]

See also

• List of investigational hallucinogens and entactogens
• List of investigational antidepressants